Plasma Therapy Market Future Scope, Growth Rate, Historical Data, Insights, Leading Players 2021 – 2028

Report Summary:

At a CAGR of 14.1% from 2021 to 2028, the global market for plasma therapy is anticipated to increase from USD 281.0 million in 2020 to USD 673.0 million by that year. On the basis of type, source, application, end user, and region, the global market is divided into subgroups.

The plasma therapy market is divided into four categories based on type: pure PRP, leucocyte-rich PRP, platelet-rich fibrin (PRF), and leukocyte-rich fibrin (L-PRF). According to estimates, the pure PRP sector will hold the largest portion of the global market in 2016. The efficacy of pure PRP therapy is one of the main factors propelling the development of this market. However, the absence of reimbursement guidelines and the wide range of plasma therapy costs are impeding the market’s expansion.

The market is divided into autologous and allogenic segments according on the source. According to estimates, the autologous sector will hold the largest portion of the global market in 2016. The autologous source market sector is expanding as a result of increased consumer awareness of plasma therapy and its recognition as an appropriate treatment for bone and other tissue mending.

Request Access Full Report is Available:@

COVID-19 Pandemic

The plasma therapy market is estimated to increase at a CAGR of 16.3% during the analysis period, compared to a CAGR of 14.6% in the pre-pandemic scenario from 2019 to 2026, according to the report. During the forecast period, market expansion is anticipated to be aided by rising awareness of the value of plasma therapy in the treatment of therapeutic conditions and oral health. In addition, it is anticipated that the rising elderly population worldwide, along with the rise in sports injuries and orthopaedic problems, will fuel market expansion.

Post-Pandemic Perspective

It is anticipated that throughout the anticipated period, the market’s growth will be strengthened by the rising investments made by governmental organisations to raise public knowledge about the use of plasma therapy in the treatment of coronavirus. Additionally, the market is anticipated to have tremendous expansion throughout the post-pandemic period as a result of the increasing acceptance of plasma therapy to give improved treatment for a number of bodily illnesses, including those of the knee, ankle, shoulder, and other parts.

Major players in the plasma therapy market include BioLife Plasma Services (U.S.), Cambryn Biologics LLC (U.S.), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB (France), Bio Products Laboratory Ltd. (U.K.), China Biologic Products, Inc. (China), and Octapharma (Switzerland).

Request a Sample Copy of the Research Report:@

This report categorizes the plasma therapy market into the following segments:

By Type

  • Pure PRP
  • Leucocyte-rich PRP
  • Pure Platelet-rich Fibrin (PRF)
  • Leukocyte-rich Fibrin (L-PRF)

By Source

  • Autologous
  • Allogenic

By Application

  • Orthopedics
    • Arthritis
    • Chronic Tendinitis
    • Bone Repair & Regeneration
  • Dermatology
    • Androgenic Alopecia
    • Plastic Surgery
  • Dental
  • Cardiac Muscle Injury
  • Nerve Injury
  • Others

By End User

  • Hospitals & Clinics
  • Research Institutions

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
Back to top